Astrazeneca (AZN) Cash & Equivalents (2009 - 2026)

Astrazeneca (AZN) has reported Cash & Equivalents for 18 consecutive years, with $7.6 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 44.55% year-over-year to $7.6 billion; the TTM figure through Mar 2026 stood at $7.6 billion (up 44.55% YoY), while the FY2025 annual figure was $5.7 billion, up 370.04% from the prior year.
• Cash & Equivalents came in at $7.6 billion for Q1 2026 at Astrazeneca, up from $5.7 billion in the prior quarter.
• The five-year high for Cash & Equivalents was $8.1 billion in Q3 2025, with the low at $1.2 billion in Q4 2024.
• Average Cash & Equivalents over 5 years is $5.8 billion, with a median of $5.8 billion recorded in 2022.
• Across the five-year window, Cash & Equivalents tumbled 79.2% in 2024 and surged 370.04% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $6.2 billion in 2022, then fell by 5.29% to $5.8 billion in 2023, then sank by 79.2% to $1.2 billion in 2024, then soared by 370.04% to $5.7 billion in 2025, then surged by 32.38% to $7.6 billion in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $7.6 billion, $5.7 billion, and $8.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.